First Republic Investment Management Inc. bought a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 4,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $682,000.

A number of other hedge funds have also recently added to or reduced their stakes in JAZZ. US Bancorp DE grew its stake in shares of Jazz Pharmaceuticals by 94.4% during the 2nd quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 368 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Jazz Pharmaceuticals by 9.8% during the 2nd quarter. Russell Investments Group Ltd. now owns 16,576 shares of the specialty pharmaceutical company’s stock valued at $2,578,000 after buying an additional 1,483 shares during the period. Janney Montgomery Scott LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $211,000. World Asset Management Inc grew its stake in shares of Jazz Pharmaceuticals by 1.9% during the 2nd quarter. World Asset Management Inc now owns 1,441 shares of the specialty pharmaceutical company’s stock valued at $224,000 after buying an additional 27 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $249,000. 91.30% of the stock is owned by hedge funds and other institutional investors.

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the company’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $150.00, for a total transaction of $150,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Iain Mcgill sold 8,000 shares of the company’s stock in a transaction on Friday, November 17th. The stock was sold at an average price of $133.42, for a total transaction of $1,067,360.00. Following the sale, the senior vice president now directly owns 28,383 shares of the company’s stock, valued at $3,786,859.86. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,552 shares of company stock valued at $2,549,643. 4.30% of the stock is owned by corporate insiders.

Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $135.53 on Friday. The company has a current ratio of 3.10, a quick ratio of 2.94 and a debt-to-equity ratio of 0.63. Jazz Pharmaceuticals PLC has a 12-month low of $104.82 and a 12-month high of $163.75. The firm has a market cap of $8,430.84, a price-to-earnings ratio of 17.65, a P/E/G ratio of 0.91 and a beta of 0.98.

Several analysts have recently issued reports on JAZZ shares. Cowen set a $190.00 price objective on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, August 21st. HC Wainwright started coverage on shares of Jazz Pharmaceuticals in a research note on Friday, August 25th. They set a “neutral” rating and a $144.00 price objective for the company. Wells Fargo & Company reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Stifel Nicolaus reissued a “buy” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, August 30th. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 29th. Two analysts have rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $181.28.

WARNING: This piece was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/first-republic-investment-management-inc-takes-682000-position-in-jazz-pharmaceuticals-plc-jazz/1767204.html.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.